S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Forecast, Price & News

$6.52
+0.29 (+4.65%)
(As of 10/3/2023 ET)
Compare
Today's Range
$6.30
$6.60
50-Day Range
$6.12
$9.30
52-Week Range
$4.65
$12.53
Volume
11,270 shs
Average Volume
11,206 shs
Market Capitalization
$35.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Molecular Templates MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.1% Upside
$15.00 Price Target
Short Interest
Bearish
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.65mentions of Molecular Templates in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$2 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.15) to ($2.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

329th out of 966 stocks

Pharmaceutical Preparations Industry

127th out of 438 stocks


MTEM stock logo

About Molecular Templates (NASDAQ:MTEM) Stock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

MTEM Price History

MTEM Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
After layoffs, Molecular Templates overhauls C-suite
Molecular Templates launches $40M private placement
Why Is Molecular Templates (MTEM) Stock Up 36% Today?
See More Headlines
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Company Calendar

Last Earnings
8/10/2023
Today
10/03/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
111
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+130.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-92,720,000.00
Pretax Margin
-92.68%

Debt

Sales & Book Value

Annual Sales
$19.75 million
Book Value
($4.03) per share

Miscellaneous

Free Float
4,656,000
Market Cap
$35.08 million
Optionable
Not Optionable
Beta
1.45

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Eric E. Poma Ph.D. (Age 51)
    CEO, Chief Scientific Officer & Director
    Comp: $923.34k
  • Ms. Jason S KimMs. Jason S Kim (Age 48)
    Pres, CFO, Treasurer & Principal Accounting Officer
    Comp: $639.85k
  • Dr. Gabriela Gruia M.D. (Age 67)
    Interim Chief Medical Officer & Director
    Comp: $33k
  • Ms. Kristen Quigley B.A. (Age 52)
    Chief Operating Officer
  • Dr. Grace Kim
    Chief Strategy Officer & Head of IR
  • Dr. Joseph Phillips Ph.D.
    Sr. VP & Head of CMC Devel.
  • Ms. Megan C. Filoon
    Sec.













MTEM Stock - Frequently Asked Questions

Should I buy or sell Molecular Templates stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MTEM shares.
View MTEM analyst ratings
or view top-rated stocks.

What is Molecular Templates' stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for Molecular Templates' shares. Their MTEM share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 130.1% from the stock's current price.
View analysts price targets for MTEM
or view top-rated stocks among Wall Street analysts.

How have MTEM shares performed in 2023?

Molecular Templates' stock was trading at $4.92 at the beginning of the year. Since then, MTEM stock has increased by 32.5% and is now trading at $6.52.
View the best growth stocks for 2023 here
.

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MTEM earnings forecast
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($3.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.25) by $1.95. The biotechnology company earned $6.87 million during the quarter. Molecular Templates had a negative net margin of 92.78% and a negative trailing twelve-month return on equity of 1,843.37%.

When did Molecular Templates' stock split?

Molecular Templates's stock reverse split on the morning of Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $6.52.

How much money does Molecular Templates make?

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $35.08 million and generates $19.75 million in revenue each year. The biotechnology company earns $-92,720,000.00 in net income (profit) each year or ($12.4438) on an earnings per share basis.

How many employees does Molecular Templates have?

The company employs 111 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.

This page (NASDAQ:MTEM) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -